评估成人普遍接种乙型肝炎疫苗的成本效用
两种干预策略分别避免近四分之一的急性HBV感染(3剂24.8%、2剂24.6%),每获得一个QALY的社会增量成本分别为152 722美元和155 429美元。作者认为成人普遍接种乙型肝炎疫苗可能是减少HBV incidence并改善健康结局的适当策略。
要点
- 3剂普遍接种策略避免24.8%的急性HBV感染,2剂策略避免24.6%。
- 3剂与2剂策略每获得一个QALY的社会增量成本分别为152 722美元与155 429美元。
- 急性HBV感染风险对结果影响最强。
核心结论
- 作者认为成人普遍接种乙型肝炎疫苗可能是减少HBV incidence并改善健康结局的适当策略。
研究设计与样本
- 比较现行接种建议(基线)与3剂或2剂普遍接种策略(干预策略)。
- 开展多变量概率敏感性分析以识别关键输入参数。
- 所有成本以2019年美元报告。
主要发现
- 低风险人群增量接种覆盖率最高至50%、高风险人群增量为0%时,3剂策略避免24.8%的急性HBV感染,2剂策略避免24.6%。
- 3剂策略每获得一个QALY的社会增量成本为152 722美元(四分位距119 113-235 086美元)。
- 2剂策略每获得一个QALY的社会增量成本为155 429美元(四分位距120 302-242 226美元)。
- 急性HBV感染风险对结果影响最强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although effective against hepatitis B virus (HBV) infection, hepatitis B (HepB) vaccination is only recommended for infants, children, and adults at higher risk. We conducted an economic evaluation of universal HepB vaccination among US adults. METHODS: Using a decision analytic model with Markov disease progression, we compared current vaccination recommendations (baseline) with either 3-dose or 2-dose universal HepB vaccination (intervention strategies). In simulated modeling of 1 million adults distributed by age and risk groups, we quantified health benefits (quality-adjusted life years, QALYs) and costs for each strategy. Multivariable probabilistic sensitivity analyses identified key inputs. All costs reported in 2019 US dollars. RESULTS: With incremental base-case vaccination coverage up to 50% among persons at lower risk and 0% increment among persons at higher risk, each of 2 intervention strategies averted nearly one-quarter of acute HBV infections (3-dose strategy, 24.8%; 2-dose strategy, 24.6%). Societal incremental cost per QALY gained of $152 722 (interquartile range, $119 113-$235 086) and $155 429 (interquartile range, $120 302-$242 226) were estimated for 3-dose and 2-dose strategies, respectively. Risk of acute HBV infection showed the strongest influence. CONCLUSIONS: Universal adult vaccination against HBV may be an appropriate strategy for reducing HBV incidence and improving resulting health outcomes.
引用
- Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults. J Infect Dis. 2022. PMID: 35260904. doi:10.1093/infdis/jiac088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。